CAZZANIGA, MARINA ELENA

CAZZANIGA, MARINA ELENA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 117 (tempo di esecuzione: 0.049 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 01 - Articolo su rivista 2023 Cazzaniga M.Antonazzo I. C.Mantovani L. G.Cortesi P. A. +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
A second update on mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2023 Invernizzi, PietroGerussi, AlessioBiondi, AndreaBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria G.Cazzaniga, MarinaFaverio, PaolaBonfanti, Paolo +
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 01 - Articolo su rivista 2023 Cazzaniga M. E. +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Nicoletta CordaniGiuseppe PagliaRamona MeantiMaria Grazia CerritoChiara VillaMario MauriLuca MologniAntonio TorselloMarina Elena Cazzaniga +
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 01 - Articolo su rivista 2023 Bonfanti P.Cazzaniga M. E. +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 01 - Articolo su rivista 2023 Foti G.Citerio G.Valsecchi M. G.Cazzaniga M.Biondi A.Bettini L. R. +
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 01 - Articolo su rivista 2023 Nicoletta CordaniLuca MologniRocco PiazzaPietro TettamantiMario MauriMatteo VillaFederica MalighettiCamillo Di BellaMaria Grazia CerritoGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 01 - Articolo su rivista 2022 Scagliotti A.Capizzi L.Cazzaniga M. E.Ilari A.Cordani N.Albini A.Lavitrano M.Grassilli E.Cerrito M. G. +
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 01 - Articolo su rivista 2022 Gerussi, AlessioBiondi, AndreaBinatti, EleonoraBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria GraziaD'Angiò, MariellaCazzaniga, MarinaFaverio, PaolaBonfanti, PaoloInvernizzi, Pietro +
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 01 - Articolo su rivista 2022 Cazzaniga, Marina +
Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report 01 - Articolo su rivista 2022 Cazzaniga M. E. +
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 01 - Articolo su rivista 2022 Cicchiello F.Cordani N.Cerrito M. G.Cazzaniga M. E. +
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 01 - Articolo su rivista 2022 Cazzaniga M. E.Baroni S.Cicchiello F.Cordani N.Cerrito M. G. +
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 01 - Articolo su rivista 2022 Marina Elena CazzanigaNicoletta CordaniMaria Grazia Cerrito +
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything 01 - Articolo su rivista 2022 Cazzaniga, Marina Elena +